期刊文献+

江西省Ⅰ型脊髓灰质炎病毒的基因特征分析 被引量:6

Analysis of type Ⅰ gene characteristics of poliovirus of Jiangxi
原文传递
导出
摘要 目的了解江西省2009年-2014年AFP病例中脊髓灰质炎病毒的分离情况,并分析Ⅰ型脊髓灰质炎病毒疫苗相关株的基因特点。方法利用分子生物学技术,通过real-time PCR对病毒分离株进行型内鉴定,并且对毒株进行VP1编码区全基因的序列测定和分析。结果 2009年-2014年,从江西省各地送检的粪便标本中,共检出9例Ⅰ型脊髓灰质炎病毒。其有相似的核苷酸序列,其核苷酸序列长度均为906 bp,编码302个氨基酸,同源性为98.6%~99.9%,与SabinⅠ序列相比,共有15个核苷酸突变位点,每株毒株的突变率为0.11%~0.99%。结论 9株均为疫苗相关株,VP1全基因编码区发现有1株Ⅰ型毒株在突变率最高的位点2 795位发生突变,可能引起其毒力回复,应加强对其进一步监测。 Objective To understand the separation rate of poliovirus from the AFP cases in Jiangxi from 2009 to 2014,and analyze the gene characteristics of type Ⅰ vaccine poliovirus. Methods Using molecular biology technology,identify the virus strain by the real- time PCR,and VP1 sequencing was need for further determination and analysis. Results From 2009 to2014,total 9 type Ⅰ vaccine polioviruses were isolated from the feces referred by Jiangxi. They had similar nucleotide sequences,and the length of the nucleotide sequences all were 906 bp,coded 302 amino acid and the homology was 98. 6%-99. 9%. Compared the sequence with the Sabin Ⅰ,there were a total of 15 nucleotide mutations,each strain mutation rate was0. 11%- 0. 99%. Conclusion The total 9 stains were all vaccine poliovirus,and 1 strain of type Ⅰ in VP1 the whole coding area was found mutation in the highest mutation site 2 795,which may cause the toxic response and should be strengthened its further monitoring.
出处 《中国卫生检验杂志》 CAS 2015年第17期2949-2951,共3页 Chinese Journal of Health Laboratory Technology
关键词 脊髓灰质炎病毒 VP1 序列测定 Poliovirus VP1 Sequencing
  • 相关文献

参考文献9

二级参考文献57

  • 1许文波,张勇,严冬梅,王东艳,赵蓉,叶绪芳,祝双利,李杰,安洪秋,张大勇,任刚,左树岩,温宁,刘铭,苏飞,刘桂艳,朱晖,唐牛良明,梁晓峰.Ⅰ型疫苗衍生脊髓灰质炎病毒循环的发现和基因特点[J].中国计划免疫,2005,11(4):252-259. 被引量:25
  • 2WHO. Polio laboratory manual, 4^th edified [M]. Genevn: Switzerland, 2004. 1-157.
  • 3刘丽萍 涂秋凤 于子颖.江西省2002年急性迟缓性麻痹监测系统运转情况分析[J].中华医学研究,2003,10:39-39.
  • 4Kohler KA, Banerjee K, Gary Hlady W, et al. Vaccine-associated paralytic poliomyelitis in India during 1999:decreased risk despite massive use of oral polio vaccine[J]. Bull WHO, 2002,80 (3): 210-216.
  • 5Dowdle WR, De Gourville E, Kew OM, et al. Polio eradication: the OPV paradox[J]. Rev Med Virol,2003,13(5):277-291.
  • 6Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccinederived poliovirus[J]. Science,2002,296(5566):356-359.
  • 7Shimizu H,Thorley B, Paladin FJ, et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001 [J]. J Virol, 2004,78(24): 13512-13521.
  • 8Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar [J]. Emerg Infect Dis,2003,9(7):885 - 887.
  • 9Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication[J]. Annu Rev Mierobiol, 2005,59: 587-635.
  • 10Alexander JP, Gary HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance:a review of the literature[J].J Infect Dis, 1997,175 (Suppl 1): 176-182.

共引文献46

同被引文献56

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部